Jennifer Holmes is a senior programme and transformation leader with deep experience across banking, lending and organisational design, built over a career spanning NatWest Group, HSBC and Barclays. She specialises in delivering complex change in regulated environments while keeping a sharp focus on customer and colleague experience.
Her background combines commercial lending expertise with hands‑on delivery of large‑scale operating model change, including performance management redesign, journey‑based ways of working, and service design at scale. More recently, Jennifer has been at the forefront of AI and digital workplace adoption, helping teams move beyond experimentation to real value. She supports leaders and teams to embed AI into day‑to‑day work, design agent‑ready journeys, and build confidence in new tools in a way that is human‑centred, responsible and commercially grounded.
A Business Development Director with over 40 years’ experience in the telecom, financial technology and product sectors, Melvyn has held executive leadership roles for a wide range of companies – from start-ups to some of the largest service providers. A proven background and domain knowledge empower him to support transformations for clients throughout the UK and Ireland.
AI Engineer & Consultant with 5+ years of experience across Europe and the USA building large-scale chatbots, time-series forecasting pipelines and other ML solutions for global enterprises. Passionate about innovation, he is always focused on applying AI to what truly moves the needle.
Sara Bueno Ortín is Associate Director of Global Procurement at Almirall, where she leads R&D Procurement with a focus on clinical development, outsourcing strategy, and vendor management.
She has extensive experience negotiating complex contracts with CROs, CDMOs, and central labs, optimizing cost models, and ensuring operational excellence across global clinical programs.
Sara plays a key role in defining sourcing strategies, managing strategic suppliers, and implementing digital procurement tools to enhance efficiency and compliance.
Mr. Longcor brings to Cellectar Biosciences, Inc. more than 20 years of pharmaceutical and biotech experience and was previously the Chief Business Officer for Avillion LLP. In this role, he was responsible for executing the company’s unique co-development partnership strategy. Prior to Avillion, Jarrod was the Vice President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics) where he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis valued over $700M. Prior to Rib-X, Mr. Longcor has held key positions in several small to midsized biotech companies where he was responsible for business development, strategic planning and operations. Jarrod holds a Bachelor of Science degree from Dickinson College, a Master of Science from Boston University School of Medicine and a Master of Business Administration from Saint Joseph’s University’s Haub School of Business.
Dr. Jeffrey S. Humphrey is CMO at Voro Therapeutics based in San Diego. He is an accomplished physician-scientist and senior biotech executive with more than two decades of leadership in global oncology drug development, spanning small molecules, antibodies, ADCs, radiopharmaceuticals, and epigenetic therapies. Harvard-educated and trained at Case Western Reserve, Johns Hopkins, and the National Cancer Institute, he has led early and late-stage clinical programs, overseen 11 NDA/BLA/MAA filings with 10 approvals, guiding development of three first-in-class medicines to U.S. and EU approval during his tenure as CMO/CDO at Kyowa Kirin. His career includes key roles at Bayer, Pfizer, and Bristol Myers Squibb—where he contributed to major launches such as Nexavar, Yervoy, and Sprycel—as well as CMO positions at Constellation Pharmaceuticals, Magenta Therapeutics, and Lantheus Holdings. He served on the Board of Directors of Cyteir Therapeutics and co-founded an early-stage venture, Charged Bio. Widely published with 60 scientific papers, Dr. Humphrey is recognized for building high-performing development organizations, advancing complex programs through pivotal inflection points, and integrating scientific, regulatory, and commercial strategy to drive innovation in precision oncology and next-generation therapeutics.
Kamil Sitarz is Chief Operating Officer and Management Board Member at Ryvu Therapeutics, a European clinical-stage oncology company advancing a diversified pipeline of innovative therapies. He leads corporate strategy, enterprise governance, capital planning, and cross-functional clinical development execution across a diversified oncology portfolio.
He has been instrumental in transforming Ryvu into a multi-program clinical-stage organization, embedding disciplined portfolio governance and architecting development pathways designed to enhance execution predictability in complex, high-risk oncology settings. His leadership integrates clinical strategy with capital allocation discipline, ensuring alignment across scientific ambition, regulatory positioning, operational design, and financial planning to drive sustainable enterprise value.
Under his direction, Ryvu has built and scaled a robust clinical development organization capable of delivering international Phase I/II programs across challenging hematologic indications and multi-country site networks. He has also played a key role in establishing and governing strategic clinical collaborations with leading global oncology partners, strengthening Ryvu’s development footprint and reinforcing its credibility within the international biotech ecosystem.
With a PhD in Medical Genetics and an Executive MBA, Kamil combines scientific depth with enterprise-level strategic and operational leadership to advance innovation with rigor, accountability, and long-term growth orientation.
Karin Johansson is an Associate Director and Team Leader for Clinical Sample Management within Clinical Operations at Ribocure Pharmaceuticals. In this role, she leads the planning and execution of clinical sample strategies and oversees the scientific, operational, and regulatory aspects of sample analyses in clinical trials. She holds a Master’s degree in Pharmaceutical Bioscience from the University of Gothenburg and has extensive experience across the drug development continuum. Her background includes more than15 years of hands-on laboratory research in cardiovascular disease at AstraZeneca, as well as clinical trial operations and site-based work as a clinical research nurse at Sahlgrenska University Hospital. Karin brings a unique perspective that integrates scientific, operational, and patient-centered aspects of clinical research.
Translational oncology scientist and scientific strategy leader with over a decade of experience integrating cancer genomics, mechanistic cell modeling, and biological insight to support target discovery, biomarker development, and precision oncology decision frameworks. Proven track record in translating complex multi-omics and computational outputs into biologically actionable insights and guiding cross-disciplinary teams across discovery and translational research initiatives. Experienced in bridging computational, experimental, and clinical perspectives to advance oncology research and therapeutic innovation.
I am an established Healthcare AI leader with over 15 years of experience in academia and industry, specializing in the integration of data science into the drug discovery process to enhance patient outcomes through precision medicine. My leadership philosophy centers on empathy, which I consider essential for cultivating high-performing teams.
As VP of Product Innovation & Strategy at Turbine, I lead a team driving product vision and roadmap at the intersection of science, technology, and strategy to transform drug discovery and development. My role bridges long-term innovation with near-term delivery, shaping priorities, guiding products from concept to launch, and building partnerships across pharma, biotech, and academia. By combining Turbine’s Virtual Biology platform with lab-in-the-loop innovation, we aim to deliver solutions with meaningful scientific and commercial impact for patients.
In my previous role at AZ, I led a global data science team delivering innovation in multi-modal data integration and deep insights into disease and drug mechanisms, informing critical portfolio milestones and reducing data-to-decision timelines. We leveraged the power of GenerativeAI to amplify insights from structured data representations across the drug discovery and development journey. My team’s efforts ensured the back-translation of clinical insights into early discovery, informing target discovery and patient-selection hypotheses.
My work is supported by a robust record of publications and presentations in the field of Healthcare AI.I am an established Healthcare AI leader with over 15 years of experience in academia and industry, specializing in the integration of data science into the drug discovery process to enhance patient outcomes through precision medicine. My leadership philosophy centers on empathy, which I consider essential for cultivating high-performing teams.
